跳到正文
Ahmad Tarhini· @ATarhiniMDPhD · X作者本人·· 2026-04-18评分60
正文

暂无中文译文,显示英文原文。

#AACR26 #SanDiego
@AACR
| April 20: Data supports single agent anti-tumor activity with continuous pathway inhibition in #RAS/#MAPK mutant #solidtumors & emerging best-in-class in #NRAS- & #BRAF Class II/III-mutant #melanoma | ⁦⁦
@MoffittNews
⁩

https://
aacrjournals.org/cancerres/arti
cle/86/8_Supplement/CT129/783305/Abstract-CT129-Preliminary-results-from-a-Phase-1a?searchresult=1
…

热度 10 · 7 赞 · 0 回复 · 3 转发

会议摘要
CT129按 摘要号 CT129 对上
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors

Ahmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov

读摘要原文 →

来源:Ahmad Tarhini · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org